芭田股份(002170.SZ):持股5%以上股東名稱變更為“雲南豐億企業管理中心(有限合夥)”
格隆匯5月21日丨芭田股份(002170.SZ)公佈,公司於近日收到持股5%以上股東來賓和君企業管理合夥企業(有限合夥)(“來賓和君”)的通知,其公司名稱已由“來賓和君企業管理合夥企業(有限合夥)”變更為“雲南豐億企業管理中心(有限合夥)”(“雲南豐億”),主要經營場所和經營範圍均進行了變更,除以上變更外,該股東的工商營業執照其他登記信息不變。上述工商變更登記手續目前已辦理完畢,並領取了由建水縣市場監督管理局頒發的新的《營業執照》,中國證券登記結算有限責任公司深圳分公司已完成證券賬户資料變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.